A divided Food and Drug Administration voted Tuesday to recommend including an omicron-fighting component to Covid’s updated drivers this fall. But vaccine stocks fell.
X
The Advisory Committee on Vaccines and Related Biological Products voted 19-2 in favor of omicron-targeted booster injections. This puts the FDA on track to authorize timely updated vaccines for a potential seasonal increase in Covid in the fall.
But many questions remain. Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX) tested several enhancers, including features that target only omicrons and bivalent injections. The latter target is omicron plus the ancestral strain of Covid. Complicating matters, omicron has its own subvariants.
On Tuesday, the Centers for Disease Control and Prevention said two of them, known as BA4 and BA5, account for a combined 52% of U.S. cases. The problem is that vaccine manufacturers have not had the opportunity to test vaccines targeted at these omicron derivations. Its updated features point to the former cousin BA1.
It is impossible to identify exactly which variant will be dominant in the fall, said during the meeting Dr. Peter Marks, director of the FDA’s Center for Biological Assessment and Research.
“What we’re doing today is working in a very difficult area because none of us have a glass ball,” he said. “We were trying to use every last ounce of predictive modeling and the data we have that is emerging to try to get ahead of a virus that has been very cunning. For someone who only does a few nanometers, it has been quite cunning. “
Vaccine stocks face Omicron
But in off-hours trading on today’s stock market, vaccine stocks were relatively quiet, moving less than 1% in either direction. During the regular session, the shares fell.
Pfizer shares lost 2.4% and ended the day at 50.66. Shares of its partner, BioNTech (BNTX), fell 2.7% to 139.82. Shares of Moderna skated 2.2% to 142.19. Shares of Novavax fell 5.1% to 51.06.
The matter is now addressed to the full FDA. The agency is not bound by the panel’s recommendation, but often follows the advice. If it succeeds in the FDA, the issue of the omicron vaccine will go to the CDC.
Two panelists voted against recommending an omicron upgrade. Drs. Paul Offit and Henry Bernstein. Neither offered an explanation after the vote. However, before the vote, Bernstein noted that data is still limited for drivers targeting BA4 and BA5. And Offit said he was uncomfortable with the level of protection omicron boosters have.
In recent tests, Pfizer said its omicron boost caused a 13.5-19.6-fold increase in antibodies capable of blocking omicron and its derivatives. A bivalent vaccine, which could target the omicron and the first strain, generated an increase in antibodies between 9.1 and 10.9 times, depending on the dose. Vaccine stock rose a fraction on Monday following its booming news.
Modern bivalent vaccine test
Similarly, Moderna tested a bivalent vaccine that includes an omicron control component. It resulted in a 5.4-fold increase in antibodies capable of handling omicron BA4 and BA5 subvariants.
In people previously infected with Covid, it caused a 6.3-fold increase. Currently, officials expect these specific subvariants to soon dominate Covid cases in the U.S.
Novavax is not yet licensed for a Covid primary series in the US However, biotechnology is still testing an omicron booster as well as a bivalent booster containing an anti-micron booster component. In testing, both options led to “high levels” of effectiveness, the company said in briefing documents.
Dr. Amanda Cohn, another panelist, said the recommendation does not necessarily mean reinforcements will be suggested for everyone in the fall. But voting is an important step toward authorization. Dr. Arthur Reingold made a similar assessment.
“Who gets what and when?” he asked.
Dr. Wayne Marasco also questioned the maximum effectiveness of Pfizer and Moderna messenger RNA vaccines. Novavax’s Covid vaccine, on the other hand, uses a different protein-based technology.
“We can do better and I’m not sure mRNA vaccines are giving us the best kind of immunity we can get here,” he said during the discussion.
Caring for Children
Another important piece for vaccine stocks: children. The FDA is only a week away from signing the primary injections for children under 5 years old. There are few data on the pediatric population. That fact is unacceptable, Dr. Archana Chatterjee said.
“Pediatric studies need to be done and should be done now,” he said.
Similarly, panelist Dr. Michael Nelson said the immuno-bridge, a process that deduces the effectiveness of a vaccine in different circumstances, would not be enough for children. Because children and young men are susceptible to heart inflammation after vaccination, safety and dose-response studies should be completed in young children, he argued.
He was concerned that young children “should always be behind the power curve when it comes to receiving vaccines.”
Dr. Cody Meissner also suggested that repeated booster doses could ultimately cause side effects. He suggested the matter could be especially complicated for children.
A Moderna representative said the company expects to have up-to-date data on its omicron features, an omicron-only injection and a bivalent containing an omicron control component, in infants and young children in October or November. However, these traits target BA1, not the more dominant BA4 and BA5 subvariants.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
ALSO AND MAY LIKE:
Why the Corcept Pill — and the Stock — Is Receiving Renewed Care After the Abortion Decision
From Axella to Tonix, here are the shares of hundreds of companies working in long Covid
Options trading: how to start using options, how to manage risk
Check out IBD’s investment strategy program for actionable market information
View IBD stock lists and get pass / fail scores for all your actions with IBD Digital